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Abstract
Metal-catalyzed, double Claisen rearrangement of a bis-allyloxyflavone has been utilized to enable 
a concise synthesis of the hydrobenzofuro[3,2-b]chromenone core structure of the natural products 
sanggenon A and sanggenol F. In addition, catalytic, enantioselective [4+2] cycloadditions of 2′-
hydroxychalcones have been accomplished using B(OPh)3/BINOL complexes. Asymmetric 
syntheses of the flavonoid Diels–Alder natural products sanggenons C and O have been achieved 
employing a stereodivergent reaction of a racemic mixture (stereodivergent RRM) involving [4+2] 
cycloaddition.
Sanggenon-type natural products (Figure 1) are intriguing synthetic targets due to their 
complex chemical structures and potent biological activities.1 In particular, the congener 
sanggenon C2 has antitumor, antiviral, and anti-inflammatory properties1c,d,3 which makes it 
an attractive synthetic target. Although chemical syntheses of related Diels–Alder (DA)-type 
natural products, including sorocenol B4 and brosimones A and B,5 have been achieved, 
there are no reported catalytic, enantioselective [4+2] cycloadditions of 2′-
hydroxychalcones, nor are there published reports of DA cycloadditions of complex 
flavonoid dienes. Here we report the first total syntheses of sanggenon A (1) and sanggenol 
F (2), both featuring complex benzofuro[3,2-b]chromenone structures. Further structural 
complexity was obtained employing enantioselective [4+2] cycloaddition to construct 
sanggenon C (3) and sanggenon O (4)6 using a unique stereodivergent RRM.7
Sanggenons C (3), D (5),8 and O (4) are apparent DA cycloadducts between a flavonoid 
diene (7) and a 2′-hydroxychalcone (6) (Scheme 1). Among these compounds, sanggenons C 
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and O were shown to be endo cycloadducts and epimers at C-2 and C-3. We considered 
stereodivergent RRM of chiral, racemic diene 7 as a promising strategy, assuming that issues 
of endo/exo selectivity, face selectivity, and enantioselectivity could be addressed. 
Compound 7 may be derived from dehydrogenation of the prenyl group of sanggenol F or its 
protected derivative (9).5a,9 Alternatively, 7 may be derived from isomerization of the 
chromene ring in sanggenon A or protected substrate (8).10 Sanggenol F core structure 9 
may arise from olefin cross-metathesis of precursor 10.We envisioned that 10 may be 
derived from metal-catalyzed double Claisen rearrangement11 of bisallyloxyflavone ether 
11, followed by hemiketalization.
Synthesis of 11 commenced with tetra-MOM group protection of the commercially available 
compound morin (12) and subsequent 5-allylation to afford the protected intermediate 13 
(Scheme 2). Selective 3-MOM deprotection was accomplished using NaI and a catalytic 
amount of aqueous HCl.12 In this transformation, protonation of the 4-carbonyl and O-3 of 
13 appears to activate the 3-MOM group for chemoselective deprotection. Finally, 3-
allylation and global MOM deprotection afforded the desired substrate 11 in 33% overall 
yield (5 steps).
A number of rare earth (RE) metal triflates were evaluated for double rearrangement of 11 
(Table 1).13 Among the metal triflates, Yb(OTf)3 was found to produce the double 
rearrangement product 15 in 72% yield. In this reaction, hexafluoro-2-propanol (HFIP) was 
used as a polar, non-coordinating14 cosolvent to solubilize the polar rearrangement substrate. 
Other RE triflates were found to produce 15 along with the single rearrangement product 16 
in varying ratios. Based on examination of a DFT molecular model13 for 11, there are two 
possible chelation sites between O-3, O-4 (2.85 Å) and O-5, O-4 (2.72 Å) through either 
five- or six-membered arrangements. Selective binding to either or both chelation pockets 
may occur depending on the ionic radius15 of the Lewis acid to enable 3-allyl rearrangement 
and/or 5-allyl rearrangement.16 Different modes of chelation by RE metal triflates may 
explain the product distributions observed in Table 1. For example, La(OTf)3 with a larger 
ionic radius (1.03 Å) may preferentially chelate between O-3 and O-4 with a larger binding 
pocket to afford the 3-allyl rearrangement product 16 as the major product.
After obtaining the desired hydrobenzofuro[3,2-b]chromenone core structure (±)-15 via 
double rearrangement, we investigated syntheses of the derived natural products 1 and 2. 
Although the prenyl group could be installed by cross-metathesis17 of hemiacetal (±)-15 to 
directly access (±)-sanggenol F (2), we found that silylation of (±)-15 followed by cross-
metathesis produced the tri-silyl-protected (±)-sanggenol F (±)-17 in excellent yield 
(Scheme 3). This sequence enabled purification of the final product from residual ruthenium 
byproducts. Desilylation of (±)-17 afforded (±)-2, which was dehydrogenated with 2,3-
dichloro-5,6-dicyano-1,4-benzoquinone (DDQ)10,18 to afford (±)-sanggenon A (1) in 78% 
yield.
We next evaluated 1 as a diene precursor for [4+2] cycloaddition. Treatment of 1 under 
Brønsted acidic, thermal, or photochemical conditions in the presence of silica-supported 
silver nanoparticles (AgNPs)19 and 2′-hydroxychalcone (cf. 20) as dienophile did not lead to 
the desired [4+2] cycloaddition; only decomposition of (±)-sanggenon A was observed. 
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Accordingly, we elected to prepare a protected variant of sanggenon A to serve as a diene 
equivalent. Specifically, transformation of the prenyl flavonoid (±)-17 to chromene (±)-18 
was investigated. Treatment of (±)-17 with DDQ in tetrahydrofuran (THF) cleanly afforded 
(±)-18 (73%) (Scheme 4). However, severe decomposition of 17 was observed when 
halogenated solvents (e.g. CH2Cl2, CHCl3, or PhCl) were employed. As DDQ is a strong 
electron-acceptor,20 a charge-transfer complex may be produced when an electron-donating 
solvent such as THF is employed.21 Formation of such a complex may modulate the 
reactivity of DDQ,22 which appears to largely suppress decomposition observed using 
oxidative conditions with halogenated solvents. We anticipated that the TBS-protected 
chromene 18 could generate the desired diene 19 in situ through retro 6π-electrocyclization 
followed by deprotonation/protonation (formal [1,7] hydrogen shift).23 Accordingly, (±)-18 
was employed in cycloadditions with acetylated 2′-hydroxychalcone 20 in the presence of 
AgNPs to yield a mixture of two endo cycloadducts and minimal production of exo 
diastereomers. The mixture of endo cycloadducts was sequentially treated with aqueous 
NaHCO3 and NEt3·3HF24 to yield a mixture of (±)-sanggenons C (3) and O (4) in 36% yield 
(3 steps, 4:1 d.r.).
Unfortunately, our previously developed conditions for asymmetric Claisen rearrangement11 
failed to give useful levels of enantioselectivity employing bis-allyloxyflavone substrate 11. 
We considered that sanggenons C and O are both endo cycloadducts with the same absolute 
configurations for the chiral cyclohexene moiety and epimers at both C-2 and C-3. 
Accordingly, we proposed that enantioselective [4+2] cycloaddition of chiral, racemic 
substrate 18 and dienophile 20 should efficiently deliver two natural products 
simultaneously utilizing a stereodivergent process. In our initial studies,25 we found that 
borate complexes derived from chiral 1,1′-bi-2-naphthol (BINOL)5b,26 could be used in 
catalytic, enantioselective [4+2] cycloadditions of 2′-hydroxychalcones. A two-dimensional 
screen was conducted using a number of borates (B(OPh)3, tris(p-chlorophenyl), 
tris(pentafluorophenyl), and tris(hexafluoroisopropyl) borate) and BINOL ligands. We found 
that asymmetric [4+2] cycloaddition of the model dienophile 2′-hydroxychalcone 21 and 
diene 2227 using a catalytic amount of (S)-3,3′-dibromoBINOL 23 and triphenylborate 
afforded the [4+2] cycloadducts 24 and 25 in 91% combined yield, 10:1 endo/exo ratio, with 
>99% and 41% ee, respectively (Scheme 5a). By mixing 21, 23, and B(OPh)3 in CH2Cl2, we 
obtained borate complex 26, the structure of which was confirmed by single-crystal X-ray 
structure analysis.13 The predicted absolute stereochemistry of the corresponding endo 
cycloadduct 24 based on the expected face selectivity of 26 was also confirmed by X-ray 
crystallography.13 We found that 1 equiv of phenol was also bound to the borate complex as 
shown in the X-ray crystal structure (Scheme 5b). The bound phenol could serve to further 
activate the chalcone for cycloaddition and may also protonate the cycloadduct to turnover 
the boron/BINOL catalyst for additional catalytic cycles. Wulff and coworkers have reported 
a hydrogen-bonded complex of a boroxinate catalyst and a protonated iminium substrate.26b 
We also found that treatment of crystalline 26 with diene 22 led to similar results, producing 
24 in high enantioselectivity.13 The latter result reinforces the involvement of borate 
complex 26 in the catalytic asymmetric DA cycloaddition, which is also supported by 
literature precedent.28
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We next applied this catalytic system to a stereodivergent RRM strategy to synthesize 
enantioenriched sanggenons C and O. Based on the model reaction (cf. Scheme 5), a 
catalytic amount of B(OPh)3 and (R)-BINOL 23 were used to mediate asymmetric [4+2] 
cycloaddition of diene precursor (±)-18 and dienophile 20 (Scheme 6). After sequential 
deprotection of both acetate and silyl protecting groups, promising enantioselectivities were 
observed. A number of BINOL ligands were evaluated; best results were obtained when 
B(OPh)3 and 23 were employed. A mixture of cycloadducts was observed, which was 
followed by consecutive deprotections (NaHCO3; NEt3·3HF) to afford sanggenon C (3) and 
sanggenon O (4) in 2:1 ratio with 98% and 93% ee, respectively. The high endo/exo 
selectivity (cf. Scheme 5) suggested that minimal amounts of exo diasteromers were 
generated which we were not able to isolate and characterize. In this transformation, we 
expected four different stereoisomers: sanggenon C (3) and ent-sanggenon O (4) from (2R,
3R)-18, and ent-sanggenon C (3) and sanggenon O (4) from (2S,3S)-18 (Scheme 6). As 
shown in the (R)-BINOL/B(OPh)3/chalcone complex 27, the re face of the chalcone 
dienophile is blocked by the bulky bromo substituent. As a result, the derived dienes (2R,
3R)-19 and (2S,3S)-19 approach from the si face of the chalcone 20 to afford 3 and 4. Using 
(S)-BINOL 23/B(OPh)3 as catalyst, ent-sanggenon C (3) and ent-sanggenon O (4) were 
isolated in 2:1 ratio with 99% and 93% ee, respectively.13We also noticed that, in the 
stereodivergent RRM, sanggenon C is produced in both high enantiomeric excess and 
diastereomeric ratio relative to sanggenon O. This result suggests that matched/mismatched 
cycloadditions may also be operative based on differential interactions of the chiral borate 
catalyst with both enantiomers of diene 19.
To understand the greater preference for formation of sanggenon C vs O (cf. Scheme 4), and 
the higher enantioselectivity observed for sanggenon C, we conducted computational studies 
of dienophile 27 using both enantiomers of a simplified variant of the diene (19′, TMS 
instead of TBS) to analyze the interacting complex of reagents engaging in DA 
cycloaddition.13,29 Cycloaddition models A and B are shown in Scheme 6, with the lowest 
energy conformer of diene 19. It appears that cycloaddition through model A is favored in 
comparison to the corresponding model B using (R)-BINOL, which results in greater 
amounts of sanggenon C derivatives and therefore favored production of (2R,3R) 
stereoisomers in the product mixture. Our preliminary reaction assembly calculations13 
show that there are significant steric interactions between the prenyl and phenyl groups on 
the chalcone dienophile which are likely responsible for the significantly increased energy in 
assemblies related to model B. Based on the X-ray structure of the chiral borate complex (cf. 
Scheme 5), we predicted that the use of (R)-BINOL as catalyst should yield (3″S,4″R,5″S) 
for both sanggenons C and O. This prediction is in agreement with absolute stereochemistry 
determinations reported by Nomura and coworkers.2b
In summary, we have achieved the first asymmetric syntheses of the flavonoid Diels–Alder 
natural products sanggenons C and O. The syntheses employ a Lewis acid-promoted double 
Claisen rearrangement to construct the hydrobenzofuro[3,2-b]chromenone core of 
sanggenon A and sanggenol F. The first catalytic enantioselective [4+2] cycloadditions of 2′-
hydroxychalcones have been developed using BINOL-boron catalysis. The high enantio- 
and diastereoselectivity of this catalytic system enabled a stereodivergent reaction of a 
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chiral, racemic flavonoid diene precursor to afford enantioenriched sanggenons C and O. 
Preliminary calculations of the interactions of diene–dienophile complexes support the 
stereochemical outcomes observed in stereodivergent cycloadditions. Further studies on the 
chemistry and biology of DA natural products are ongoing and will be reported in due 
course.
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Figure 1. 
Structures of sanggenon-type natural products.
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Scheme 1. 
Retrosynthetic Analyses for Sanggenons C and O
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Scheme 2. 
Synthesis of Morin Di-allyl Ethera
aReagents and conditions: (a) MOMCl (5 equiv), DIPEA (5 equiv), CH2Cl2, 0 °C to rt, 55%; 
(b) allyl-Br (1.2 equiv), Cs2CO3 (1.2 equiv), DMF, 65 °C, 12h, 93%; (c) NaI (0.8 equiv), 1 
N HCl (0.1 equiv), 40 °C, 12h, 73%; (d) allyl-Br (2.0 equiv), Cs2CO3 (2.0 equiv), DMF, 
65 °C, 12h, 96%; (e) conc. HCl, MeOH, 40 °C, 93%.
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Scheme 3. 
Syntheses of Sanggenol F and Sanggenon Aa
aReagents and conditions: (a) TBSOTf (3.2 equiv), NEt3 (3.0 equiv), CH2Cl2, rt, 6h; (b) 
Grubbs second generation catalyst (10 mol%), isobutene, 40 °C, 24h, 92%, 2 steps; (c) 
NEt3·3HF (8.0 equiv), CH3CN, 0 °C, 3h, 91%; (d) DDQ (1.2 equiv), THF, 60 °C, 12h, 78%.
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Scheme 4. 
Syntheses of (±)-Sanggenons C and Oa
aReagents and conditions: (a) DDQ (1.5 equiv), THF, 60 °C, 73%; (b) 20 (1.2 equiv), AgNP 
(0.25 mol%), AcOH (2 equiv), DCE, 65 °C, 3d; (c) sat. NaHCO3, MeOH, rt, 12h; (d) 
NEt3·3HF (8.0 equiv), CH3CN, rt, 12h, 36% (3 steps), sanggenon C (3):sanggenon O (4) = 
4:1.
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Scheme 5. 
Model Reaction and Proposed Active Complex for [4+2] Cycloaddition
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Scheme 6. 
Asymmetric Syntheses of Sanggenons C and Oa
aReagents and conditions: (a) B(OPh)3 (20 mol%), 23 (22 mol%), 20 (1 equiv), PhCF3, 
80 °C, 48h; (b) sat. NaHCO3, MeOH, rt, 12h; (c) NEt3·3HF (8.0 equiv), CH3CN, rt, 12h.
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Table 1
Lewis Acid-mediated Double Rearrangementa
entryb M(OTf)x ionic radii (pm)c yields of 15, 16 (%)
1 Yb(OTf)3 86.8 72, 0
2 Y(OTf)3 90.0 60, 36
3 Gd(OTf)3 93.8 48, 40
4 Nd(OTf)3 98.3 38, 62
5 La(OTf)3 103.2 0, 70
aSee SI for experimental details.
bAll reactions were carried out with substrate 11 (0.13 mmol) and M(OTf)3 (15 mol%) at 0.1 M in CH2Cl2/HFIP (4:1) at 50 °C.
c
For effective ionic radius, see ref 15.
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